For EGFR-mutant NSCLC patients, EGFR-TKIs are the standard first-line regimens; however, therapeutic challenges remain in subpopulations, notably those with brain metastases, who have a poor prognosis [30]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.